Algae as a Source of Bioactive Compounds to Prevent the Development of Type 2 Diabetes Mellitus

Jelena B. Popović-Djordjević¹, Jelena S. Katanić Stanković², Vladimir Mihailović³, Antia G. Pereira⁴,⁵, Paula Garcia-Oliveira⁴,⁵, Miguel A. Prieto⁴,* and Jesus Simal-Gandara⁴,*

¹University of Belgrade, Faculty of Agriculture, Department of Chemistry and Biochemistry, 11080 Belgrade, Serbia; ²University of Kragujevac, Institute for Information Technologies Kragujevac, Department of Science, 34000 Kragujevac, Serbia; ³University of Kragujevac, Faculty of Science, Department of Chemistry, 34000 Kragujevac, Serbia; ⁴Nutrition and Bromatology Group, Analytical and Food Chemistry Department, Faculty of Food Science and Technology, University of Vigo, Ourense Campus, E-32004 Ourense, Spain; ⁵Centro de Investigación de Montanha (CIMO), Instituto Politécnico de Bragança, Campus de Santa Apolonia, 5300-253 Bragança, Portugal

Abstract: Type 2 diabetes mellitus is a complicated metabolic disorder characterized by hyperglycemia and glucose intolerance. It is considered a new pandemic and its control involves numerous challenges. Although many of the measures are based on improving life habits, diet is also of vital importance due to bioactive compounds present in food. In this regard, several raw materials have been investigated whose bioactivities seem to slow the progression of this disease. Within these matrices, there are algae of importance, such as brown algae, showing to have beneficial effects on glycemic control. These pieces of evidence are increasing every day due to the development of cell or animal models, which lead to the conclusion that bioactive compounds may have direct effects on decreasing hyperglycemia, enhancing insulin secretion and preventing the formation of amyloid plaques.

Keywords: Diabetes mellitus, diabetes mellitus type 2, diet, algae, bioactive compounds, glycemic control.

1. INTRODUCTION

1.1. Definition and Classification of Diabetes

Diabetes mellitus (DM) is a complex metabolic disorder caused by the deficiency of insulin effects and characterized by a high level of blood glucose (hyperglycemia) [1]. The elevated levels of glucose in the blood can interfere with the metabolic pathways of proteins, carbohydrates, and fats in the organism causing severe complications [2]. Insulin, a peptide hormone, is produced by the β-Langerhans islet cells of the pancreas from precursors preproinsulin and proinsulin. In a normal physiological state, a higher blood glucose level (after a meal) triggers the release of insulin from the pancreas, which thereafter spark the metabolism of glucose in the liver, but also the elimination of glucose from the blood by muscle and adipose cells. All of the above lead to a reduction of high blood sugar concentration to ordinary values [2].

However, if the production and secretion of insulin (Fig. 1) are disrupted by various factors (genetic and/or environmental) or if the insulin action is injured, the organism will be producing sugar through glycogen, protein, and lipid metabolisms, leading to hyperglycemia. Besides, this state can increase protein catabolism and lipolysis and induce liver impairments manifested by metabolic acidosis and overproduction of ketone bodies [3, 4]. Additionally, in the state of diabetes, the following conditions can also develop: polyuria or forming high quantities of urine accompanied by glycosuria (high concentration of glucose in urine), polyphagia or increased appetite, polydipsia or higher need for liquids, possible weight loss, and severe consequences such as ketosis, acidosis, and coma. Hereby, there is an elevation of lipolysis and reduced possibility of amino acids entering the muscle tissues [1]. All above-
Fig. (1). Illustrative presentation of effects of insulin deficiency. Created in BioRender.com. (A higher resolution/-colour version of this figure is available in the electronic copy of the article).

mentioned factors, in particular, hyperglycemia, cause an increment of oxidative stress, boost inflammation processes, activate the polyol pathway and lead to long-term damage, micro- and macrovascular complications, severe failure of numerous organs (kidneys, eyes, brain, heart, cardiovascular system), and fatal outcome, death [3, 5].

Diabetes, as a debilitating, chronic disease, is threatening because of complications arising on different levels that can lead to serious acute and chronic manifestations. With severe problems that occur in diabetic patients, their quality of life is significantly disturbed and life expectancy is reduced [6].

There are several types of diabetes, but two are the most prominent. Type 1 diabetes mellitus (T1DM), formerly known as insulin-dependent DM or “juvenile diabetes”, represents an autoimmune disorder in which β–cells in the pancreatic islets are rapidly destroyed, causing impaired insulin secretion, which further leads to insulin deficiency in the organism [7, 8]. T1DM affects mostly children and adolescents and accounts for 3–5% of total cases [1]. The children with T1DM are
inclined to develop ketoacidosis, so the essential therapy is based on insulin administration on a daily basis to control the glucose concentration in the blood [3].

On the other hand, type 2 diabetes mellitus (T2DM), formerly identified as non-insulin-dependent diabetes mellitus, is characteristic for adults. Generally, the incidence of T2DM increases in patients who are more than 30 years old [6]. T2DM occurs because of impaired insulin release from the pancreatic β-cells followed by insulin resistance (IR) in peripheral tissues (brain, liver, skeletal muscle, and adipose tissues). Because of IR, the secretion of insulin increases greatly, but also the hyperglycemia [1, 8].

Another type of diabetes, which receives more attention nowadays, is gestational diabetes (GDM). Conferring with the Centers for Disease Control and Prevention, it is deemed a category of diabetes that occurs first time during pregnancy [9]. The cause of this manifestation is still unknown. On a yearly level, around 10% of all pregnancies in the USA are affected by this type of diabetes [10]. It usually develops in middle pregnancy and may cause the development of chronic diabetes in the mother, as well as the baby.

Still, T2DM holds a devastating record affecting more than 90% of total diabetes cases in Western countries. Nowadays, there is an alarming upward trend of T2DM development in children [3]. The genetic predisposition, ethnicity, older age, unhealthy lifestyle, smoking, and bad dietary habits promote the probability of T2DM development. The initial stage in T2DM is indicated by hyperfunction of pancreatic β-cells, causing their dysfunction and promoting apoptosis [7]. It is interesting that years can pass before the presence of type 2 diabetes is properly diagnosed due to the lack of recognizing the symptoms of this disease. T2DM in patients, initially, does not require insulin treatment since the first symptoms could be monitored and prevented. The routine injection of insulin is the most common therapy, and also the administration of synthetic drugs. The antidiabetic drugs have different targets of actions, such as reducing the resistance of insulin, postponing the carbohydrate absorption, boosting the release of insulin, the sensitivity to insulin can be enhanced by drugs and some can act in the same way as insulin [11, 12]. The therapies with antidiabetics are mostly considered to be lifelong, but many drugs are reported to exert quite serious side effects, moderate like nausea or diarrhea, weakness, weight gain, but also severe like haematuria, proteinuria, gastrointestinal disturbances, and cardiovascular mortality [4, 5, 12]. Therefore, the quest for new drug candidates with advanced antidiabetic properties and the absence of negative effects still continues. In this respect, medicinal plants, mushrooms, algae, and pure natural compounds may be used as safe alternatives with many benefits for human health, among which crucial are antidiabetic properties with various modes of action [6, 13-15].

1.2. Considering Diabetes as a New Pandemic of the 21st Century

World Health Organization (WHO) proclaimed diabetes as an epidemic illness, and the unique non-infectious disease with such categorization [11]. Factors such as behavior, genetics and socioeconomics have a great impact on diabetes. The literature shows that the global burden of diabetes is on the rise [16, 17]. According to the recent data, it was estimated that about 463 million adult people (age 20-79 years) worldwide were affected by diabetes in 2019, which is four-fold higher compared to the number in the 1980s [8]. It should be emphasized that nearly 50% of people with diabetes are not aware of the fact that they have diabetes [17]. Continuing this trend, the number of people with diabetes will increase over 600 million by 2040 [11, 17]. Data related to the global burden of dia-betes, its prevalence and associated risks are summarized in Fig. (2).

The observation regarding the area of living and the county income suggests that higher prevalence is in urban rather than in rural areas, and in high-income than in low-income countries. Among adults with diabetes in 2019, nearly half of them lived in five nations: China, India, the USA, Pakistan and Brazil [18]. Looking by gender, the prevalence is higher in men compared to women [19]. In 2012, about 3.7 million deaths were associated with diabetes or glucose levels higher than...
optimal, and 43% of deaths occurred in people younger than 70 [5]. The latest figures show that about 11.3% of global deaths are due to diabetes, on a global level, and almost half of these deaths are people under 60 years of age [18].

Among the major types of this chronic disease, T2DM is the most prevalent, accounting for about 90% of people with diabetes [3, 11, 20]. Children and adolescents (aged under 20) are the most vulnerable groups with respect to T1DM. On the other hand, T2DM is diagnosed in adults (>20), but there has been some evidence that it is increasing in some countries among children and adolescents [18]. Risk factors closely linked to the development of T2DM are obesity/overweight, lack of physical activity, smoking habits, excessive consumption of alcoholic beverages, ethnicity (South Asian, Afro-Caribbean, Hispanic), etc. [21]. Unlike for T2DM, genetic susceptibility and unknown environmental causes are risks for T1DM. Unfortunately, with the standard of living increasing, so is the prevalence of both diabetes types worldwide [17, 21, 22].

Although DM is a chronic disorder, individuals with diabetes can lead a normal life at the same time, taking care that diabetes is under control. Lifestyle changes (changes in daily habits) and nutritional therapy are essential components of any diabetes control plan. Lifestyle changes can be an effective mode to control diabetes. Better blood sugar control can slow the evolution of long-term complications. Nutrition modification in people with diabetes is often very complex, and should take into consideration individual nutritional needs, cultural preferences and lifestyle. Often, the help of a skilled dietitian is crucial in ensuring the proper nutrition therapy. Changing the type and quantity of food intake can help people with diabetes to lose weight, improve control of blood sugar levels and lower blood cholesterol levels and blood pressure. Dietary practices differ from region to region, but socioeconomic status also has a great influence on diet habits. The main advice of diabetes experts is to reduce carbohydrate levels in diet along with reducing the fat intake and to use higher quality food ingredients [23]. A well-balanced diet should contain carbohydrates (preferably from grains, fruits, vegetables and low-fat milk), proteins, fats, suitable quantities of vitamins and minerals from natural food sources [24]. The usual days’ meals and snacks should supply about 1,500–2,000 calories provided by carbohydrates,
proteins and fats in approximate relation of 50, 20 and 30%, respectively [25].

Besides proper nutrition, physical activity is also important for people with diabetes. Even people with long-term diabetes or its complications can benefit from exercise. The exercise improves the patients’ cardiovascular condition and helps with weight loss, lowers blood pressure, improves lipid profiles, in some cases improves blood sugar control and leads to a better overall condition of the body. In some people, it can also prevent the development of T2DM [26, 27].

1.3. Problems Arising from T2DM

As a metabolic disorder, diabetes of any type is associated with different health problems and shorter life expectancy. Over time, elevated glucose levels may provoke both acute and chronic complications and development of eye diseases (retinopathy), cardiovascular diseases, chronic kidney disease, nerve and vascular damage and stroke blindness [16, 18]. The risk of fetal death and other complications is increased in pregnancy if diabetes is not properly controlled [18, 27]. In addition to adequate anti-diabetic therapy (both drug and nutrition), psychological adjustment to diabetes is equally important, as diabetes-related emotional distress may negatively influence glycemic control [28].

Economic and social impacts imposed by diabetes should not be neglected. For the treatment of diabetes and its complications, billions of dollars are spent every year [22]. This includes both direct (treatment of complications) and indirect (premature death, disability and other health complications) costs of the annual global health expenditures associated with the condition. The discrepancy between diabetes-related health expenditure and the number of people suffering from diabetes in countries of different income levels is notable. It is estimated that 95% of the global health expenditure on diabetes is allocated from the world’s richest countries, North America (57%), Europe (28%) and Western Pacific (10%) [29]. The mortality related to diabetes-related premature deaths (90%) and all deaths due to diabetes (87%) is the highest in low- and middle-income countries. The low rate of diabetes diagnosis and difficulties in acquiring the proper medical care in these countries are closely associated with such mortality outcomes [18].

Nonetheless, several trials have demonstrated that changes in lifestyle and pharmacology could postpone or prevent the development of T2DM. Additional studies showed that implementing lifestyle changes for diabetes prevention in primary medical care and other approaches such as remote support (phone, email, DVD, and the Web), meal replacement, etc. might give satisfactory results. It is necessary to put effort at both national and international levels to identify persons that are at risk of diabetes, and systematically implement these interventions. Health education in schools, food policy, acts that promote early detection and intensive management of type 2 diabetes, as parts of social interventions should be promoted [30]. Regular control of metabolic parameters (glucose, HbA1c, lipids, blood pressure, body weight, and renal function), and the quality of life, are important factors in providing effective outcome in diabetes and diabetes-related diseases management.

2. MECHANISMS OF NATURAL PRODUCTS-BASED DIETS IN TREATING IR

Considering the increase in the number of people with DM, it is necessary to investigate mechanisms to combat it. However, there are also several measures whose objective is to prevent the appearance of the disease. IR may be a predictor of T2DM, so taking the measures to prevent this problem could reduce the number of patients with T2DM [31]. Basically, these measures focus on changes in diet and lifestyle, especially in the case of the aging population [32]. In this regard, increasing the consumption of plants and algae may be interesting, as they have considered effective tools for the prevention and control of T2DM [33]. In fact, leguminous plants, whole grains, vegetables, fruits, nuts and seeds, have been linked with inferior rates of obesity, hypertension, hyperlipidemia, cardiovascular mortality and cancer. Therefore, it is of great interest to study eating patterns [34]. Nevertheless, additional studies are still required to adequately comprehend the action of macronutrients and factors such as the amount in which they are present or the metabolic and genetic differences between persons. All of this makes it complicated to standardize a diet, requiring their monitoring.

Nowadays, there is a negative trend between high levels of glycemic index and consumption of saturated fatty acids and carbohydrates. In contrast, diets with a low content in carbohydrates and high content in proteins induce weight loss, but cause long-term metabolic damage [35]. Moreover, high-fat (especially saturated) diets have negative effects on insulin sensitivity and could contribute to the development of T2DM [36, 37]. In this regard, fiber and phytonutrient consumption, which are only present in plant foods, is remarkable. Different studies show that a high consumption of fiber (> 25 g / day in women and > 38 g / day in men) reduces the probability of developing T2DM by 20-30%, observing a higher effect when con-
Individuals show an increase in imiterweight and, therefore, digestive fibers [38]. However, these fermentable fibers give rise to short-chain fatty acids that increase glucose response and insulin signaling and sensitivity [39]. Regarding cereals, their fibers prevent the absorption of proteins, regulating the metabolism of amino acids [38]. Moreover, fibers have a satiating effect, which leads to weight loss and consequent reduction in IR [40]. IR begins in the hypothalamus, creating an imbalance of satiety and hunger signals. This imbalance causes an excessive increase in calorie consumption, compromising the storage of the excess of fat, which can have a noteworthy role in the control of IR [41]. Thus, satiety is important to manage IR.

Another interesting mechanism to prevent T2DM is the promotion of healthy body weight since visceral obesity (not subcutaneous) leads to increased IR and excessive accumulation of lipids in the liver, augmenting the risk of developing the disease. The accumulation of lipids can result in impaired insulin signaling or inflammation, which entails deterioration of the action of insulin due to the action of macrophages. In the case of subcutaneous fat, this does not happen since it prevents the fat from reaching the liver [42]. In conclusion, to improve metabolic parameters of IR it is preferable to maintain a negative energy balance better than maintaining a stable lower weight [43].

However, obesity is also associated with variations in the intestinal microbiota, which are potential contributors to metabolic diseases. In this regard, high-weight individuals show an increase in Firmicutes and Actinobacteria and a decrease in Bacteroidetes groups. These changes in the intestinal microbiota caused alterations in the intestinal permeability, which lead to greater activation of the inflammatory pathways and impaired insulin signaling. Specifically, a reduction in insulin receptor phosphorylation, insulin receptor substrate (IRS) and protein kinase B (Akt) was observed, while phosphorylation IRS-1 serine inhibitory was increased. Therefore, the modification of the intestinal microbiota gives rise to diverse signaling activations and alterations, which can be an attractive option for the management of obesity and T2DM [44]. Several genera have been described to be positively related with T2DM, among them Ruminococcus, Fusobacterium, and Blautia, whereas the genera Bifidobacterium, Bacteroides, Faecalibacterium, Akkermansia and Roseburia were negatively associated with T2DM [45]. Therefore, knowing the role of the human gut microbiota in obesity and T2DM is a priority [46].

Exposure to certain types of compounds also generates IR, such as streptozotocin (a nitrosamine-related compound) and nitrosamines. The last are metabolites with a high presence in processed foods and whose chronic exposure prompts to IR and may progress to T2DM and other diseases, like non-alcoholic steatohepatitis and Alzheimer’s disease. Thus, it is crucial to enhance the detection and decrease exposure to nitrosamines [47]. This can happen, for example, with the consumption of red meat which will also have heme iron [48]. High levels of iron in the diet are also an important factor in T2DM, since this compound has a direct and causal role in the pathogenesis of the disease, interceded by β-cell insufficiency and IR. Other adverse effects are related to insulin secretion and sensitivity, as well as adipokine levels and metabolic flexibility [49]. The scientific evidence indicates the great importance of iron in the diabetic condition since it influences the risk of developing the disease and the risk of suffering complications of the disease in an advanced stage [50]. However, although biomarkers of the iron metabolism pathway related to the appearance of DM are known, the underlying mechanisms are not yet discovered. Plasma levels of ferritin and TSAT are strongly related to various indicators of IR in young and healthy individuals. The weakest relationship has been observed with the indicators of short and long-term glucose controls. Therefore, iron metabolism has a pronounced influence in IR, nonetheless has a minor influence on blood glucose levels, with inflammation and/or obesity playing a crucial role [51]. Insulin sensitivity decrease due to the modulation of the transcription and membrane expression/affinity of insulin receptor expression in hepatocytes, which produces changes in insulin-dependent gene expression. Thus, in people suffering from non-alcoholic fatty liver disease, a positive effect of iron depletion can be achieved with the help of increased insulin clearance and a decrease in IR [52].

It also has to be taken into account the development of advanced glycation end products (AGEs), formed due to non-enzymatic modification of proteins by reducing sugars. During aging, the formation of AGEs increases, being this growth faster in DM. In fact, AGEs are implied in the pathogenesis of diabetic vascular difficulties. The interaction between AGEs and its receptor has been proven to cause oxidative stress and inflammation, which are factors closely associated with IR and later in the progress of diabetes [53, 54]. To prevent IR and its consequences, different strategies can...
be applied with the common objective of limiting the accumulation and action of AGEs [55]. Moreover, several studies proved that AGEs also present negative effects on non-diabetic states, characterized by an increase in AGEs concentration and impaired glucose homeostasis. This effect encompasses activation of endoplasmic reticulum- and inflammatory-stress and repression of glucose transporter type 4 (GLUT4) expression [56]. Therefore, a diet with low content of AGEs may have less risk of developing T2DM [57]. Through control and limitation of AGEs intake, native oxidative defenses and insulin sensitivity may be preserved [58].

As conclusions, among the mechanisms to prevent IR, we found maintaining healthy body weights, eating patterns, diets with high content in fiber and phytonutrients, and decrease in saturated fats, advanced glycation end products, nitrosamines and heme iron as the most important ones [33].

3. EMERGING BOTANICAL ADVANCES FOR TREATMENT AND PREVENTION OF T2DM

As mentioned before, the control of a high blood glucose level after eating is the main goal in T2DM patients. For this purpose, a restrictive diet, physical activity, and pharmacological methods are employed. The reduction of carbohydrates’ digestion and their bioavailability, stimulation of insulin release, reduction of IR, increasing sensitivity to insulin, and mimicking insulin function are some of the mechanisms in which antidiabetic drugs are involved [12]. Several of these drugs are derived from natural products, mainly from plants and microbes. A guanidine derivative, galegine, isolated from Galega officinalis L. (Fabaceae) possesses a clear antidiabetic effect and its chemical structure is relatively comparable to the antidiabetic drug metformin [6, 11]. Pycnogenol is a case of a natural compound with antidiabetic properties obtained from Pinus pinaster Aiton (Pinaceae), which possesses α-glucosidase inhibitory activity. Also, acarbose is presumably the most extensively used enzyme inhibitor for carbohydrate digestion obtained from microbial origin [6, 16]. Besides the historical and ethnopharmacological importance of medicinal plants in the use of treatment of T2DM, antidiabetic preparations of botanical origin still have significant value in the treatment of DM and its comorbidities. The research of botanical products with antidiabetic potential has been stimulated by the numerous side effects of the long-term use of oral hypoglycemic drugs, limited efficacy of existing medications and the development of health complications associated with unregulated hyperglycemia in T2DM patients [6, 8, 16].

In vitro laboratory and preclinical studies, as well as several clinical studies in T2DM patients, reported that medicinal herbs, spices, food plants, and mushrooms had shown the potential to improve the condition of diabetes mellitus [14, 59-61]. In recent years, many research papers and reviews dealing with the role of antidiabetic potential of medicinal plants and their secondary metabolites, including clinical trials, have been published. The most studied plant species and plants with the greatest potential in therapy for T2DM referred to these studies and reviews were bitter melon (Momordica charantia L.), cinnamon (Cinnamomum cassia Siebold), aloe (Aloe barbadensis Mill), nettle (Urtica dioica), chamomile (Matricaria recutita L.), turmeric (Curcuma longa L.), “yerba mate” (Ilex paraguariensis A.St.-Hil.), green and black tea (Camellia sinensis (L.) Kuntze), fenugreek (Trigonella foenum-graecum L.), garlic (Allium sativum L.), and onion (Allium cepa L.) [3, 6, 62, 63]. The mechanisms of natural products from botanical sources for controlling glycemia include inhibition of α-glucosidase and α-amylase as targets for carbohydrate breakdown reduction and prevention of the glucose increase in plasma [64], influence on glucose uptake and glucose transporters, and regulation of insulin secretion [6, 61]. It is also approved that some plant preparations improved metabolic abnormalities caused by diabetes such as advanced glycation end-product formation, free radical over-production, and oxidative stress [5].

According to Choudhury et al. [61], most of the highly effective plants possess multimodal activities on the control of T2DM. In Fig. (3) [73-85], some of the active principles of main medicinal plants with anti-diabetic effects are summarized. Cinnamon has been considered as a nutraceutical for T2DM since 1990. Numerous studies on animal models show that the consumption of cinnamon stimulates insulin secretion, enhancing the production of gut glucagonlike peptide 1 (GLP-1) and induces overexpression of GLUT4, which increases the glucose uptake in the myocytes and adipocytes. Moreover, cinnamon also possesses a preventive effect on complications of diabetes, mainly by lowering glycation end-product formation, thought high phenolic content with antioxidant effects [6, 65]. Also, several mechanisms of hypoglycemic activity of M. charantia (bitter melon) have been proposed in different in vitro and in vivo studies. This plant increases adiponectin release, improves glucose uptake, and activates peroxisome proliferator-activated receptors α and γ, regulating lipid and glucose hemostasis, and control IR [66, 67]. Sceds of fenugreek (T. foenum-graecum) are widely used as a herbal medicine for diabetes. In addition, relevant scientific studies reported its antidia-
Fig. (3). Some of the active principles of main medicinal plants with antidiabetic effects [73-85].

Antidiabetic effects by inhibiting α-amylase and sucrase activities, stimulating insulin secretion, and increasing the number of insulin receptors [68]. Similar effects were reported for *U. dioica* [69-71]. Green and black tea (*C. sinensis*) is reported as an epigallocatechin gallate-enriched plant with antidiabetic properties and positive effects on diabetes complications [72]. Several mush-rooms are also reported as a potential class anti-diabetic phytotherapeutics. Some medicinal and edible mushrooms showed the potential to reduce blood glu-cose levels, stimulate insulin secretion, improve in-sulin sensitivity, and reduce hepatic glucose output [60]. Considering mechanisms of action of botanical natural products in the treatment and control of T2DM, different polyherbal formulations with hypoglycemic activity were developed. The studies on diabetic animals showed that polyherbal formulations available on the market possess antihyperglycemic effects and may improve endogenous antioxidant status [61].

There are several clinical studies, including plants, herbal formulations, or herbal extracts as antidiabetic agents. However, the number of *in vitro* screening and preclinical studies in animals of medicinal plants used...
for treating diabetes are more numerous compared with clinical trials. The major interest in research of plant species in the treatment of T2DM could be the increase of clinical trials and systematic reviews that can establish definitive conclusions for using a certain plant in antidiabetic therapy.

4. ALGAE AS A NEW RESOURCE

Nowadays, several authors have considered the algae as organisms not only of high ecological importance but also of economic significance [86]. In fact, the use of algae has undergone exponential growth and their application is already possible in various areas such as energy production, agriculture, food science, cosmeceutical and pharmacology [87]. One of its emerging applications is their use as a source of bioactive compounds with interesting biological properties at a medical level, including compounds for the prevention of T2DM. In this field, numerous investigations have been carried out using various species, especially with brown algae from the orders Laminariales and Fucales [88].

Among the compounds from algae for the prevention of T2DM, several could be highlighted, specially sugars. For example, alginate has demonstrated advantageous properties on glucose metabolism [89] and fucoidan has been reported to reduce α-glucosidase activity, blood glucose and glycated hemoglobin and glucagon-like peptide-1 in type 2 diabetes patients [90]. Other interesting compounds are phlorotannins, which present numerous antidiabetic activities, such as α-glucosidase and α-amylase inhibitory effect, modulation of glucose uptake effect in skeletal muscle, protein tyrosine phosphatase 1B (PTP1B) enzyme inhibition, improvement of insulin sensitivity in type 2 diabetic db/db mice, and protective effect against DM complication [91]. Pigments also have beneficial properties. For example, fucoxanthin, present in brown algae, has displayed inhibitory activities against α-amylase, α-glucosidase and glucose oxidase in 3T3-L1 cells linked to T2DM [92] Chemical structures of algae’ compounds with antidiabetic activity have been presented in Fig. (4). In this work, the species have been selected according to previous bibliographic research and their presence in the Iberian Peninsula.

4.1. Brown Algae

This group of algae present characteristic compounds, such as phlorotannins, fucoids, fucoxanthin or fucosterols, whose antidiabetic properties have been evaluated and their importance has increased in recent years [93]. Within this group, multiple species have been investigated. Those available in the study region and that have been employed in several studies are shown below and have been summarized in Table 1.

4.1.1. Ecklonia spp.

The genus Ecklonia has been one of the most studied due to its extensive variety of therapeutic and health properties and biological activities, including antidiabetic, antioxidant, anti-inflammatory and hypolipidemic, among others [143]. Regarding antidiabetic activity, it is attributed to phenolic compounds, which have demonstrated inhibitory activity against two enzymes belonging to the gluconeogenesis pathway: phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. This inhibition leads to the regulation of blood glucose levels, reducing the risk of hyperglycemia [97]. The phlorotannin eckol, considered one of the most representative compounds of this genus, has shown numerous biological activities, such as antioxidant, anti-inflammatory, antimicrobial, hepatoprotective or anti-hypertensive. According to this variety of properties, several studies have been focused in elucidating pharmacological potential [144].

4.1.2. Laminaria spp.

Within this genus, several species have been traditionally consumed in Asian cuisine, but the most prominent is Laminaria japonica, traditionally known as “kombu”. This species contains a great number of compounds with confirmed biological activities and applications. According to the different scientific studies, the compounds responsible for the antidiabetic activity of Laminaria spp. are polysaccharides, butyl-i-sobutyl-phthalate and phenols. These compounds have been evaluated, both in vitro and in vivo. In fact, the Laminariaceae family was already used in traditional Chinese medicine for the treatment of DM [107].

4.1.3. Saccharina spp.

Like genus Laminaria, Saccharina spp. have been consumed in China and other oriental countries as traditional seafood products and also as medicine in traditional medicine. Saccharina japonica is one of the most studied algae within the genus, being rich in fucoidan, alginate, and laminarin [145]. Its antidiabetic properties have been associated with these polysaccharides since they augmented insulin levels, accumulation of glycogen in the liver and reduced the blood glucose level in diabetic mice, among other molecular mechanisms to palliate diabetic pathologies [146]. Although research is still preliminary and more studies should be conducted, this genus may have great potential for diabetes and obesity.
4.1.4. Sargassum spp.

Sargassum spp. contain numerous bioactive compounds, like phenolic compounds, sulphated polysaccharides, dietary fibers, carotenoids, etc. These compounds have been proven to exert various activities like antioxidant, anti-inflammatory, anti-tumor and also anti-diabetic, among others [147]. Among the species studied, Sargassum fusiforme, formerly known as Hizikia fusiformis, is one of the most relevant, but other species have shown antidiabetic properties. Other species of the same genus also have anti-diabetic properties. For example, Sargassum polycystum suppressed
Table 1. Activity of the different species of brown algae genera mentioned and their compounds of interest.

<table>
<thead>
<tr>
<th>Algae</th>
<th>Compounds</th>
<th>Extract / Format</th>
<th>Main Outcomes</th>
<th>Test System</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. cava</td>
<td>Phloroglucinol</td>
<td>C.E</td>
<td>α-glucosidase and α-amylase inhibition (IC\textsubscript{50} 10.8 and 124.9 µmol/L, respectively)</td>
<td>In vitro</td>
<td>[94]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>C.E</td>
<td>α-glucosidase and α-amylase inhibition (IC\textsubscript{50} 0.58 and 0.35 mg/mL, respectively)</td>
<td>In vitro</td>
<td>[95]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>Supplement</td>
<td>Treatment against high glucose-induced oxidative stress</td>
<td>In vitro</td>
<td>[96]</td>
</tr>
<tr>
<td></td>
<td>Phloroglucinol</td>
<td>C.E</td>
<td>Inhibiting hepatic gluconeogenesis via modulating the AMP-activated protein kinase α signaling pathway</td>
<td>In vivo (mice)</td>
<td>[97]</td>
</tr>
<tr>
<td></td>
<td>Dieckol</td>
<td>W</td>
<td>Improving the glucose and lipid metabolism and antioxidant enzymes</td>
<td>In vivo (mice)</td>
<td>[98]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>Powder</td>
<td>Hypoglycemic and hypolipidemic agent, prevents the loss of β-cell mass resulting in the increase of insulin secretary capacity</td>
<td>In vivo (mice)</td>
<td>[99]</td>
</tr>
<tr>
<td>E. maxima</td>
<td>Fucoidan</td>
<td>W</td>
<td>α-glucosidase inhibition (IC\textsubscript{50} 0.27–0.31 mg/mL)</td>
<td>In vitro</td>
<td>[100]</td>
</tr>
<tr>
<td></td>
<td>Eckol, dibenzo [1,4] dioxine-2,4,7,9-tetraol, phloroglucinol</td>
<td>EA</td>
<td>α-glucosidase inhibition (IC\textsubscript{50} 11.16, 33.69 and 1991 µM, respectively)</td>
<td>In vitro</td>
<td>[101]</td>
</tr>
<tr>
<td>E. kurome</td>
<td>Phlorotannins</td>
<td>C.E</td>
<td>Inhibitory activities on carbohydrate-hydrolyzing enzymes and decreased postprandial blood glucose levels</td>
<td>In vivo (mice)</td>
<td>[102]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>Gametophytes</td>
<td>Regulated metabolism by manipulating the balance among cytokines, including interferon-gamma or leptin, resulting in the down-regulation of blood glucose</td>
<td>In vivo (mice)</td>
<td>[103]</td>
</tr>
<tr>
<td>E. stolonifera</td>
<td>Phlorofucofuroeckol-A</td>
<td>EtOH</td>
<td>Advanced glycation end-products formation inhibition (40% inhibition)</td>
<td>In vitro</td>
<td>[104]</td>
</tr>
<tr>
<td></td>
<td>Polyphenols</td>
<td>MeOH</td>
<td>Suppressed the increase in plasma glucose and lipid peroxidation, inhibition of α-glucosidase</td>
<td>In vivo</td>
<td>[105]</td>
</tr>
<tr>
<td></td>
<td>Phlorotannins</td>
<td>C.E</td>
<td>PTP1B and α-glucosidase inhibitory activity (IC\textsubscript{50}, ranging between 0.56 to 2.64 µM and 1.37 to 6.13 µM, respectively)</td>
<td>In vitro</td>
<td>[106]</td>
</tr>
<tr>
<td>Laminaria spp.</td>
<td>N.A</td>
<td>W</td>
<td>Effects on the postprandial blood glucose level in carbohydrate-loaded mice.</td>
<td>In vivo (mice)</td>
<td>[107]</td>
</tr>
<tr>
<td>L. digitata</td>
<td>Alginates</td>
<td>W</td>
<td>Reduced blood glucose and insulin responses</td>
<td>In vivo (pigs)</td>
<td>[108]</td>
</tr>
<tr>
<td>L. japonica</td>
<td>BIP</td>
<td>C.E</td>
<td>α-glucosidase inhibition (IC\textsubscript{50} 35.00 µM)</td>
<td>In vitro</td>
<td>[109]</td>
</tr>
<tr>
<td></td>
<td>BIP</td>
<td>EA</td>
<td>α-glucosidase inhibition (IC\textsubscript{50} 38.00 µM)</td>
<td>In vitro and in vivo (mice)</td>
<td>[110]</td>
</tr>
<tr>
<td></td>
<td>BIP</td>
<td>EA</td>
<td>α-glucosidase inhibition (IC\textsubscript{50} 19.23 µM)</td>
<td>In vitro</td>
<td>[111]</td>
</tr>
<tr>
<td></td>
<td>Phoephorbide A</td>
<td>MeOH</td>
<td>Aldose reductase activity (IC\textsubscript{50} 12.31 µM), prevention of diabetic complications</td>
<td>In vitro</td>
<td>[112]</td>
</tr>
<tr>
<td></td>
<td>Polyphenols</td>
<td>W</td>
<td>α-glucosidase inhibition, attenuate muscle IR</td>
<td>In vitro and in vivo (mice)</td>
<td>[113]</td>
</tr>
<tr>
<td></td>
<td>Polysaccharides</td>
<td>W</td>
<td>Reduced blood glucose and increased the levels of insulin and amylin in serum</td>
<td>In vivo (mice)</td>
<td>[114]</td>
</tr>
<tr>
<td></td>
<td>Polysaccharides</td>
<td>W</td>
<td>Prevented body-weight loss, increased serum insulin levels</td>
<td>In vivo (mice)</td>
<td>[115]</td>
</tr>
</tbody>
</table>

(Table 1) contd...
<table>
<thead>
<tr>
<th>Species</th>
<th>Compounds</th>
<th>Extraction Method</th>
<th>Effect</th>
<th>Conditions</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>S. latissima</em></td>
<td>Pheophorbide-A, Pheophytin-A</td>
<td>C.E</td>
<td>Aldose reductase inhibition (IC$_{50}$ 12.31 µM)</td>
<td>In vivo (mice)</td>
<td>[93]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pellets</td>
<td>Lower bodyweight, lower HbA1c and insulin levels</td>
<td>In vivo (mice)</td>
<td>[116]</td>
</tr>
<tr>
<td></td>
<td>Fucoidan</td>
<td>Water</td>
<td>Stimulating the pancreatic release of insulin</td>
<td>In vivo</td>
<td>[117]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>Power</td>
<td>Influences glycemic control lowers blood lipids, and increases antioxidant enzymes activity</td>
<td>In vivo (humans)</td>
<td>[118]</td>
</tr>
<tr>
<td></td>
<td>Phenolic compounds</td>
<td>Fermented</td>
<td>α-amylase and rat intestinal α-glucosidase inhibition (IC$_{50}$ 0.98 µM)</td>
<td>In vivo (rats)</td>
<td>[119]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>Powder</td>
<td>Recovery of the the islet cell secreting function and reduction of the level of fasting blood glucose by an antioxidant effect</td>
<td>In vivo (rats)</td>
<td>[120]</td>
</tr>
<tr>
<td></td>
<td>Fucosterol, fucoxanthin</td>
<td>MeOH</td>
<td>α-glucosidase inhibition (IC$_{50}$ 1.4 µM)</td>
<td>In vitro (rats)</td>
<td>[121]</td>
</tr>
<tr>
<td></td>
<td>Phenols</td>
<td>Vegetable extract with algae</td>
<td>α-glucosidase inhibition, weaker α-amylase inhibition activity</td>
<td>In vitro (rats)</td>
<td>[122]</td>
</tr>
<tr>
<td></td>
<td>Polyphenols</td>
<td>W</td>
<td>α-glucosidase inhibition, decreased tumor necrosis, attenuated muscle IR (IC$_{50}$ 12 µM)</td>
<td>In vitro and in vivo (mice)</td>
<td>[113]</td>
</tr>
<tr>
<td></td>
<td>Fucoidan</td>
<td>EtOH</td>
<td>Decreased fasting blood glucose, diet and water intake. Attenuation of pathological change in heart and liver. Better liver function. Suppression of oxidative stress.</td>
<td>In vivo (mice)</td>
<td>[123]</td>
</tr>
<tr>
<td></td>
<td>Polysaccharides</td>
<td>C.E</td>
<td>Renal protection due to inhibition of the expression inflammatory compounds</td>
<td>In vivo (rats)</td>
<td>[124]</td>
</tr>
<tr>
<td><em>S. fusiforme</em></td>
<td>Phlorotannins</td>
<td>MeOH</td>
<td>Decrease postprandial blood glucose level via inhibiting α-glucosidase (IC$_{50}$ = 0.12 mg/mL)</td>
<td>In vitro and in vivo (mice)</td>
<td>[125]</td>
</tr>
<tr>
<td><em>S. ringgoldianum</em></td>
<td></td>
<td>EtOH</td>
<td>Decreased fasting blood glucose and HOMA-IR. Regeneration and reconstitution of damaged pancreatic β-cells</td>
<td>In vivo (rats)</td>
<td>[126]</td>
</tr>
<tr>
<td><em>S. oligocystum</em></td>
<td>N.A</td>
<td>EtOH</td>
<td>Effective hypoglycemic and hypolipidemic effect</td>
<td>In vivo (rats)</td>
<td>[127]</td>
</tr>
<tr>
<td><em>S. longiotom</em></td>
<td>N.A</td>
<td>EtOH</td>
<td>Renal protection due to inhibition of the expression inflammatory compounds</td>
<td>In vivo (rats)</td>
<td>[128]</td>
</tr>
<tr>
<td><em>S. duplicatum</em></td>
<td>Laminaran</td>
<td>EtOH</td>
<td>α-glucosidase inhibition (IC$_{50}$ 36.13 ppm)</td>
<td>In vitro (rats)</td>
<td>[129]</td>
</tr>
<tr>
<td><em>S. patens</em></td>
<td>Phloroglucinol</td>
<td>EtOH</td>
<td>Inhibition of α-glucosidase (IC$<em>{50}$ 25.4 µg/mL), human salivary and pancreatic α-amylases (IC$</em>{50}$ 3.2 µg/mL)</td>
<td>In vivo (rats)</td>
<td>[130]</td>
</tr>
<tr>
<td><em>S. polycystum</em></td>
<td>Pigments</td>
<td>EtOH, W</td>
<td>Reduced blood glucose, HbA1c, triglyceride and serum total cholesterol levels</td>
<td>In vivo (rat)</td>
<td>[131]</td>
</tr>
<tr>
<td><em>S. hemiphyllum</em></td>
<td>Polyphenols, fucoxanthin</td>
<td>EtOH, AcO, W</td>
<td>α-amylase (IC$<em>{50}$ 0.35 mg/mL), maltase (IC$</em>{50}$ 0.09 mg/mL) and sucrase (IC$_{50}$ 1.89 mg/mL) inhibition</td>
<td>In vitro</td>
<td>[132]</td>
</tr>
<tr>
<td><em>S. hystrix</em></td>
<td>N.A</td>
<td>EtOH</td>
<td>Decreases the levels of preprandial and postprandial glucose, prevents necrosis</td>
<td>In vivo (rat)</td>
<td>[133]</td>
</tr>
<tr>
<td><em>S. binderi</em></td>
<td>N.A</td>
<td>W</td>
<td>α-glucosidase inhibition (IC$_{50}$ 6.39 mg/mL)</td>
<td>In vitro (mice)</td>
<td>[134]</td>
</tr>
<tr>
<td><em>S. serratifolium</em></td>
<td></td>
<td>EtOH</td>
<td>Plastoquinones PTP1B and α-glucosidase inhibition (IC$_{50}$ 1.83 to 7.04 and 3.16 to 24.16 µg/mL, respectively).</td>
<td>In vitro (rats)</td>
<td>[135]</td>
</tr>
<tr>
<td><em>U. pinnatifida</em></td>
<td>Phenols</td>
<td>C.E</td>
<td>α-glucosidase inhibition, weaker α-amylase inhibition activity</td>
<td>In vitro (mice)</td>
<td>[136]</td>
</tr>
<tr>
<td></td>
<td>Fucoxanthin</td>
<td>C.E</td>
<td>Regulates mRNA expression of inflammatory adipocytokines involved in IR</td>
<td>In vitro and in vivo (mice)</td>
<td>[137]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>Dried</td>
<td>Reduced IR</td>
<td>In vivo (humans)</td>
<td>[138]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>Dried</td>
<td>Reduces postprandial glucose concentration</td>
<td>In vivo (humans)</td>
<td>[139]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>Dried</td>
<td>Improves postprandialglucose homeostasis, reduces glycemic excursions in prediabetes</td>
<td>In vivo (humans)</td>
<td>[140]</td>
</tr>
</tbody>
</table>

(Table 1 contd...
endocrine cell damage and necrotic cells, which have been attributed to antioxidant-related mechanisms [148]. According to these results, it could be concluded that the extracts obtained with brown algae have curative properties on DM and may be considered as a new approach for the therapy of this disease.

4.1.5. Undaria Pinnatifida

This species, traditionally known as wakame, has been widely consumed [149]. It contains carbohydrates, proteins and many types of secondary metabolites, such as polyphenols. These compounds present strong biological activities, including antioxidant, anticancer, anti-inflammatory and anti-diabetes [150]. Several benefits have been described when used as supplements in the diet, including in glucose metabolism [151]. The main component responsible for this activity is alginate, which reduces glucose uptake in humans [152]. Other important components are the fucoidans, which regulate the blood glucose homeostasis, and also fucoxanthin. In particular, this carotenoid has been reported to inhibit PTP1B, human recombinant aldose reductase (HRAR), rat lens aldose reductase (RLAR), AGEs formation, regulates blood glucose and insulin levels, suppress monocyte chemoattractant protein-1 expression and promote beta-3 adrenergic receptor (Adrb3) and GLUT4 expression [153].

4.2. Green Algae

Although most antidiabetic compounds of algae are characteristic of brown algae, there are also other compounds with this activity present in green and red algae, such as polyphenolic compounds, dietary fibers or unsaturated fatty acids [153]. For example, the administration of Ulva rigida reduced blood glucose levels in diabetic rats submitted to streptozotocin and also complications related to the disease. In this study, the authors considered that phenolic compounds were involved in the anti-hyperglycemic effects observed [154]. Another example of green algae with anti-diabetic effects is Capsosiphon fulvescens. Capsosulfesin A, capsosulfesin B and chalinasterol from this species has demonstrated to inhibit aldose reductase [155]. Several studies have estimated the antidiabetic potential of Chlorella sp., which has inhibitory effects against AGEs production, especially pentosidine and N(6)-Carboxymethyllysine. In addition, carotenoids of this mi-croalgae, such as neoxanthin, lutein or violaxanthin, have shown strong antiglycation activity [156]. These properties and also the ability to inhibit α-amylase and α-glucosidase enzymes, have encouraged the development of different patents which use these species in the treatment of diabetes. For example, the biotechnology company Solazyme of the United States owns a patent that employs C. protothecoides for people with im-paired glucose tolerance and DM (US 8747834 B2). Other examples can be found in Table 2.

4.3. Red Algae

Red algae also contain compounds of great interest for the treatment of T2DM. As an example, Odonthalia corymbifera’ bromophenols show α-glucosidase inhibition, with IC₅₀ values varying between 0.098 μM and 89.0 μM. Specifically, the compound bis(2,3-dibromo-4,5-dihydroxybenzyl) ether was the most potent. Similar results were observed in Symphyocladia latius-cula, with IC₅₀ of 0.03 μM for the same compounds, followed by 2,3,6-tribromo-4,5-dihydroxybenzyl alco-hol with IC₅₀ of 11.0 μM [169]. Another red alga, Poly-opes lancifolia, inhibited α-glucosidase from Bacillus stea-thermophilus and S. cerevisiae, with IC₅₀ of 0.12 and 0.098 μM, respectively. The alga was also effective against rat intestinal maltase (and sucrase, with IC₅₀ of 1.20 and 1.00 mM, respectively [170]. This activity is also present in other species such as Grateloupia elliptica [166], Rhodomela confervoides [171] or Laurencia similis [172]. Phenolic extracts obtained from Palmaria sp. showed inhibitory effects on α-amylase enzyme [164]. Protein hydrolysates of the same
Table 2. Activities of the other two big groups of algae.

<table>
<thead>
<tr>
<th>Algae</th>
<th>Compounds</th>
<th>Extract/Format</th>
<th>Main outcomes</th>
<th>Test system</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Green algae</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. lentillifera</td>
<td>N.A</td>
<td>EtOH</td>
<td>Reduction of DM-related enzymes activity, increment of insulin secretion and glucose uptake</td>
<td>In vitro</td>
<td>[157]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>EtOH</td>
<td>Regulated glucose uptake and homeostasis via the PI3K/AKT pathway</td>
<td>In vivo (mice)</td>
<td>[158]</td>
</tr>
<tr>
<td>C. sertularioides</td>
<td>N.A</td>
<td>W</td>
<td>Hypoglycemic effect, alterations in the lipid levels</td>
<td>In vivo (mice)</td>
<td>[159]</td>
</tr>
<tr>
<td>C. macrophysa</td>
<td>Phenolic compounds</td>
<td>EtOH</td>
<td>Reduction of dipeptidyl peptidase-IV and α-glucosidase enzyme activities. Inhibition of cell death and inflammation</td>
<td>In vivo</td>
<td>[160]</td>
</tr>
<tr>
<td>Chlorella spp.</td>
<td>Carotenoids, fatty acids</td>
<td>EA</td>
<td>Inhibition of the AGEs formation</td>
<td>In vitro</td>
<td>[156]</td>
</tr>
<tr>
<td>C. zofingiensis</td>
<td>Astaxanthin</td>
<td>EA</td>
<td>Antiglycative capacities (inhibition of AGEs formation, glucose autoxidation, glycation-induced protein oxidation)</td>
<td>In vitro</td>
<td>[161]</td>
</tr>
<tr>
<td>U. rigida</td>
<td>N.A</td>
<td>Raw</td>
<td>Reduce plasma glucose levels</td>
<td>In vivo (rats)</td>
<td>[154]</td>
</tr>
<tr>
<td>U. lactuca</td>
<td>Polysaccharides</td>
<td>W</td>
<td>Inhibition of enzymes</td>
<td>In vivo (rats)</td>
<td>[162]</td>
</tr>
<tr>
<td>Red algae</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P. palmata</td>
<td>Proteins</td>
<td>W</td>
<td>Dipeptidyl peptidase IV inhibition</td>
<td>In vitro</td>
<td>[163]</td>
</tr>
<tr>
<td></td>
<td>Phenols</td>
<td>C.E</td>
<td>α-amylase and α-glucosidase inhibition</td>
<td>In vitro</td>
<td>[164]</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>Raw, dehydrated</td>
<td>Lower bodyweight, HbA1c and insulin levels</td>
<td>In vivo (mice)</td>
<td>[116]</td>
</tr>
<tr>
<td>R. confervoides</td>
<td>3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6- (ethoxymethyl)benzyl)benzene-1,2-diol</td>
<td>C.E</td>
<td>PTP1B inhibition</td>
<td>In vitro</td>
<td>[165]</td>
</tr>
<tr>
<td>G. elliptica</td>
<td>2,4,6-tribromophenol, 2,4-dibromophenol</td>
<td>C.E</td>
<td>α-glucosidase, sucrase and maltase inhibition</td>
<td>In vitro</td>
<td>[166]</td>
</tr>
<tr>
<td>S. latiuscula</td>
<td>Bromophenols</td>
<td>C.E</td>
<td>Aldose reductase inhibition</td>
<td>In vitro</td>
<td>[167]</td>
</tr>
<tr>
<td>G. amansii</td>
<td>N.A</td>
<td>Raw</td>
<td>regulates plasma glucose and lipid levels and prevents adipose tissue accumulation</td>
<td>In vivo (rats)</td>
<td>[168]</td>
</tr>
</tbody>
</table>

**Compounds:** Not Analyzed (N.A)  
**Solvent:** Water (W); Ethanol (EtOH); Ethyl Acetate (EA); Commercial extract (C.E)  
**Diabetes-related compounds and enzymes:** Glycated hemoglobin (HbA1c); Protein tyrosine phosphatase 1B (PTP1B); Advanced glycation end-products (AGEs); phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt)

alga also showed potential anti-diabetes properties [163]. Other examples can be seen in Table 2.

5. FUTURE PERSPECTIVES

The number of patients with diabetes continues to growth, being considered a pandemic. This trend involves a greater production of drugs to treat the disease and more research into methods to prevent it. This is a great interest, not only in terms of the health and wel-

l-being of the population, but also economically since the production of drugs is expensive. Persistent efforts and novel ideas are the driving force for the development of relevant drugs [173].

The approach to treat this disease has changed in the last few decades, especially at the dietary level. In the past, nutritional management of diabetes drastically eliminated all kinds of carbohydrate-rich foods [174], but nowadays, it is known that this disease is more
linked to the quality of the carbohydrates and the fats ingested than to the proportion that they represent in the total of ingested macronutrients [175]. It is considered that the best dietary management of T2DM and IR consists of a balanced diet adapted to the associated pathologies of the patient. Dietary management of each patient must be carried out by the dietician in a detailed and individualized form. However, for all cases, the management of T2DM requires well-monitored glycemic control in order to control the progressive deterioration of β-cell function.

Conventional drugs and insulin are effective in treating the disease but unable to repair the associated metabolic and glucoregulatory dysfunctions, so combination therapies (drugs and diet) are gaining interest [176]. In this regard, incretin-based therapy and peptide analogs should be highlighted, since this method would allow to restore and preserve β-cell function and stop the progression of T2DM [177]. Furthermore, the increasing knowledge of the metabolism of this disease has demonstrated the benefits of phenolic compounds [178]. However, it is important to explore the common background of DM-mediated changes in pharmacokinetic and bioactivities of these dietary compounds, elucidate related mechanisms, and develop novel methods to improve the benefits of phenolic compounds and clinical outcomes for T2DM [179]. Phenolic compounds may be provided through the diet in foods such as tea or coffee, although its bioavailability is small [180]. Due to their low bioavailability, it is important to develop products with greater bioavailability. In this regard, the study of new plants and algae is remarkable as they are matrices rich in phenolic compounds. Moreover, several technologies should be developed to improve the bioavailability of dietary polyphenols, including nanotechnology and homogenization, as bioavailability depends on bioaccessibility, molecular structures, transporters, metabolizing enzymes, and food matrix effect [179]. Furthermore, the advancement in sophisticated omics methodologies has allowed the determination of molecules involved in nutritional genomics, metagenomics and other environmental exposures (mainly as markers of compliance). Consequently, the incorporation of techniques such as gene sequencing and omics will lead towards a molecular understanding of complex organisms [181].

However, to carry out all these advances in the market, it is necessary to take into account the current legislation. As it has been observed, many plant matrices have been used in traditional remedies to treat this disease, so they would not be subject to the new food legislation. However, the continuous progress of science, the discovery of new species and the study of others not used to date mean that many of them are considered as new food, which makes the process of commercialization much slower [182].

**CONCLUSION**

The treatment of patients with DM is considered a medical challenge due to the continuous increase in patients. This disease also depends on numerous factors that make its prevention more complex. In recent years, new therapeutic strategies have been developed based on traditional knowledge and the use of traditional plants and new sources with high anti-diabetic potential, such as algae. In fact, numerous scientific studies have demonstrated the beneficial properties of algal extracts and compounds (such as polysaccharides, phenolic compounds or pigments), both in *vitro* and *in vivo* studies. However, more clinical trials are still needed to determine its potential to develop new foods or anti-diabetic products. In addition, algae are highly accepted by consumers for being well valued as natural products. Dissemination of knowledge of diabetes as well as how to prevent or treat it to a wider audience is a potential method to control the diabetes epidemic. In the future, medical perspectives and new drug developments will be implemented to change the landscape of antidiabetic therapeutic study.

**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Generic</th>
<th>DM</th>
<th>=</th>
<th>Diabetes mellitus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GDM</td>
<td>=</td>
<td>Gestational diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td>HOMA-IR</td>
<td>=</td>
<td>Homeostatic Model Assessment for Insulin Resistance</td>
</tr>
<tr>
<td></td>
<td>IR</td>
<td>=</td>
<td>Insulin resistance</td>
</tr>
<tr>
<td></td>
<td>N.A</td>
<td>=</td>
<td>Not analyzed</td>
</tr>
<tr>
<td></td>
<td>T1DM</td>
<td>=</td>
<td>Type 1 diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td>T2DM</td>
<td>=</td>
<td>Type 2 diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td>WHO</td>
<td>=</td>
<td>World health organization</td>
</tr>
<tr>
<td></td>
<td>Diabetic-related compounds</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adrb3</td>
<td>=</td>
<td>beta-3 adrenergic receptor</td>
</tr>
<tr>
<td></td>
<td>AGEs</td>
<td>=</td>
<td>Advanced glycation end-products</td>
</tr>
<tr>
<td></td>
<td>Akt</td>
<td>=</td>
<td>protein kinase B</td>
</tr>
<tr>
<td></td>
<td>GLP-1</td>
<td>=</td>
<td>glucagonlike peptide 1</td>
</tr>
</tbody>
</table>
GLUT4 = Glucose transporter type 4
HbA1c = Glycated hemoglobin
HRAR = Human recombinant aldose reductase
IRS = Insulin receptor substrate
PI3K/Akt = phosphatidylinositol 3-kinase/protein kinase B
PTP1B = Protein tyrosine phosphatase 1B
RLAR = Rat lens aldose reductase
UCP-1 = Uncoupling protein one
Solvents
AcO = Acetone
C.E = Commercial extract
EA = Ethyl Acetate
EtOH = Ethanol
MeOH = Methanol
W = Water

CONSENT FOR PUBLICATION
Not applicable.

FUNDING
This study has been funded by the Ministry of Education, Science, and Technological Development of the Republic of Serbia (Grants Nos. 451-03-9/2021-14/200026, 451-03-9/2021-14/200378 and 451-03-9/2021-14/200122. In Spain and Portugal, the research leading to these results received financial support from Programa de Cooperación Interreg V-A España—Portugal (POCTEP) 2014–2020; MICINN supporting the Ramón&Cajal grant for M.A. Prieto; to Xunta de Galicia and University of Vigo supporting the pre-doctoral grants for A.G. Pereira, and P. García-Oliveira; to Ibero-American Program on Science and Technology for financial support. This project has received funding from the Bio Based Industries Joint Undertaking (JU); the JU receives support from the European Union’s Horizon 2020 research and innovation program and the Bio Based Industries Consortium.

REFERENCES
[7] De Paoli, M.; Werstuck, G.H. Role of estrogen in type 1 and type 2 diabetes mellitus: a review of clinical and pre-
Algae as a Source of Bioactive Compounds


Algae as a Source of Bioactive Compounds


http://dx.doi.org/10.1038/oby.2008.505 PMID: 19008868


http://dx.doi.org/10.1016/j.bmc.2019.05.035 PMID: 31196754


Algae as a Source of Bioactive Compounds


[148] Motshakler, M.; Ebrahimii, M.; Goh, Y.M.; Othman, H.H.; Hair-Bejo, M.; Mohamed, S. Effects of brown seaweed (Sargassum polycystum) extracts on kidney, liver, and pan-
http://dx.doi.org/10.1155/2014/379407 PMID: 24516503

http://dx.doi.org/10.24275/uzam/izt/dcbs/hidro/2016v26n2/DeLara

http://dx.doi.org/10.13040/IJPSR.0975-8232.10(3).1014-24

http://dx.doi.org/10.1016/j.foodchem.2010.12.043 PMID: 25213937

http://dx.doi.org/10.3109/13813455.2013.775159 PMID: 23638862

http://dx.doi.org/10.1007/s10811-013-0017-4

http://dx.doi.org/10.1016/j.foodchem.2010.11.111

http://dx.doi.org/10.3390/md11020350 PMID: 2336483

http://dx.doi.org/10.1016/j.phytochem.2008.09.007 PMID: 18951591

http://dx.doi.org/10.1021/np040199j PMID: 15844965

http://dx.doi.org/10.1007/s10610-015-0003-0

http://dx.doi.org/10.1016/j.foodchem.2009.10.018

http://dx.doi.org/10.12980/APJTB.4.2014APJTB.4-0091 PMID: 25183280


